Arvinas

ARVN · NASDAQ

$7.66+$0.40 (+5.51%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.26

Latest news

NewsSep 25, 7:25 AM ET
Arvinas Q2 2026 Earnings Call Transcript
NewsAug 4, 9:10 AM ET
Transcript: Arvinas Q2 2026 Earnings Conference Call
NewsAug 4, 7:05 AM ET
Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate
Press releaseAug 4, 7:00 AM ETGlobe Newswire
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseJun 4, 8:00 AM ETGlobe Newswire
Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease
NewsJun 1, 7:55 AM ET
Full Transcript: Arvinas Q1 2026 Earnings Call
NewsMay 13, 1:54 PM ETAvi Kapoor
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
NewsMay 12, 2:38 PM ETVandana Singh
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
NewsMay 12, 7:21 AM ET
Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
NewsMay 12, 7:08 AM ET
Arvinas Q1 EPS $(0.90) Misses $(0.87) Estimate, Sales $15.600M Miss $18.097M Estimate
Press releaseMay 12, 7:05 AM ETGlobe Newswire
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseMay 12, 7:00 AM ETGlobe Newswire
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
NewsMay 4, 12:30 PM ETVandana Singh
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
Press releaseMay 1, 12:43 PM ETGlobe Newswire
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
NewsFeb 25, 3:01 PM ET
5 Analysts Assess Arvinas: What You Need To Know
NewsFeb 23, 3:02 PM ET
Arvinas's Earnings Outlook
Press releaseFeb 10, 5:31 PM ETPRNewswire
PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
Press releaseJan 8, 4:30 PM ETBusiness Wire
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
NewsJan 6, 9:01 AM ET
The Analyst Verdict: Arvinas In The Eyes Of 7 Experts
NewsNov 18, 12:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsNov 18, 7:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsOct 15, 6:01 PM ET
Forecasting The Future: 7 Analyst Projections For Arvinas
NewsSep 17, 8:00 AM ET
What 4 Analyst Ratings Have To Say About Arvinas
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Press releaseJun 23, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm
NewsJun 18, 11:15 AM ETAvi Kapoor
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields (CORRECTED)
Press releaseJun 11, 8:30 AM ETGlobe Newswire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
NewsJun 9, 9:19 AM ETAvi Kapoor
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Press releaseJun 7, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Press releaseJun 6, 12:20 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
NewsJun 6, 10:18 AM ETVandana Singh
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
NewsJun 2, 5:00 PM ET
What Analysts Are Saying About Arvinas Stock
Press releaseJun 2, 2:09 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Press releaseJun 1, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Press releaseMay 28, 8:00 PM ETBusiness Wire
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN)
Press releaseMay 28, 9:00 AM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Press releaseMay 26, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Press releaseMay 22, 9:00 AM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Press releaseMay 21, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm
Press releaseMay 20, 9:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Press releaseMay 18, 10:00 AM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Arvinas Q2 2026 Earnings Call Transcript

Transcript: Arvinas Q2 2026 Earnings Conference Call

Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease

Full Transcript: Arvinas Q1 2026 Earnings Call

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel

Earnings Scheduled For May 12, 2026

Arvinas Q1 EPS $(0.90) Misses $(0.87) Estimate, Sales $15.600M Miss $18.097M Estimate

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

5 Analysts Assess Arvinas: What You Need To Know

Arvinas's Earnings Outlook

PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

The Analyst Verdict: Arvinas In The Eyes Of 7 Experts

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Forecasting The Future: 7 Analyst Projections For Arvinas

What 4 Analyst Ratings Have To Say About Arvinas

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields (CORRECTED)

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

What Analysts Are Saying About Arvinas Stock

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN